drug · small molecule

OZURDEX

updated 2mo ago

by $ABBV AbbVie Inc.🔗 ChEMBL

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 75 approved and 174 investigational indications.

targets

Glucocorticoid receptor

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

OZURDEX

trade names

Aeroseb-dex, Decaderm, Decadron, Decadron-75, Decaspray, Dexa-sine

generic

DEXAMETHASONE

MOA

12.1 Mechanism of Action Dexamethasone, a corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells.

indication

1 INDICATIONS AND USAGE OZURDEX is a corticosteroid indicated for: The treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) ( 1.1 ) The treatment of non-infectious uveitis affecting the posterior segment of the eye ( 1.2 ) The treatment of diabetic macular edema ( 1.3 ) 1.1 Retinal Vein Occlusion OZURDEX ® (dexamethasone intravitreal implant) is indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). 1.2 Posterior Segment Uveitis OZURDEX is indicated for the treatment of non-infectious uveitis affecting the posterior segment of the eye. 1.3 Diabetic Macular Edema OZURDEX is indicated for the treatment of diabetic macular edema.

OZURDEX

targets

all catalysts(0)

News(0)

Report a data issue

🐶 often sniffed alongside

comments(0)

Trials studying OZURDEX